https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-05-01 / Expert Opin Biol Ther 2009 May;9(5):539-64
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-05-01 / Expert Opin Biol Ther 2009 May;9(5):539-642009-05-01 00:00:002019-02-15 08:44:25Dendritic cells: therapy and imaging
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-05-01 / Prostate 2009 May;69(6):571-84
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-05-01 / Prostate 2009 May;69(6):571-842009-05-01 00:00:002019-02-15 08:53:02Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-05-01 / Cancer Invest. 2009 May;27(4):361-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-05-01 / Cancer Invest. 2009 May;27(4):361-82009-05-01 00:00:002019-02-15 08:50:14Tumor vaccines for breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-05-01 / J. Immunother. 2009 May;32(4):333-40
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-05-01 / J. Immunother. 2009 May;32(4):333-402009-05-01 00:00:002019-02-15 08:48:40Synergistic effect of dendritic cell vaccination and anti-CD20 antibody treatment in the therapy of murine lymphoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-05-01 / IDrugs 2009 May;12(5):297-301
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-05-01 / IDrugs 2009 May;12(5):297-3012009-05-01 00:00:002019-02-15 08:44:21Antitumor vaccines, immunotherapy and the immunological constant of rejection
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-05-01 / J. Immunother. 2009 May;32(4):363-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-05-01 / J. Immunother. 2009 May;32(4):363-92009-05-01 00:00:002019-02-15 08:44:23Conditioning vaccination site with irradiated MIP-3alpha-transfected tumor cells enhances efficacy of dendritic cell-based cancer vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-05-01 / Expert Rev Vaccines 2009 May;8(5):567-76
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-05-01 / Expert Rev Vaccines 2009 May;8(5):567-762009-05-01 00:00:002019-02-15 08:44:24Novel strategies for improved cancer vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-04-11 / Urol. Oncol. 2010 May-Jun;28(3):290-5
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-04-11 / Urol. Oncol. 2010 May-Jun;28(3):290-52009-04-11 00:00:002019-02-15 08:53:01Tumor specific cytotoxicity and telomerase down-regulation in prostate cancer by autologous dendritic cells loaded with whole tumor cell antigens
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-04-10 / Cancer Immunol. Immunother. 2009 Jul;58(7):1169-74
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-04-10 / Cancer Immunol. Immunother. 2009 Jul;58(7):1169-742009-04-10 00:00:002019-02-15 08:48:09Vaccination strategies in patients with renal cell carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-04-01 / Pancreas 2009 Apr;38(3):e69-74
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-04-01 / Pancreas 2009 Apr;38(3):e69-742009-04-01 00:00:002019-02-15 08:52:34A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer
